COST EFFECTIVENESS IN TREATING GUILLAIN BARRE SYNDROME PATIENTS WITH INTRAVENOUS IMMUNOGLOBULIN AS COMPARED TO THERAPEUTIC PLASMA EXCHANGE
- Conditions
- Health Condition 1: null- All patients were either Bed ridden and on ventilator support system.
- Registration Number
- CTRI/2018/04/013278
- Lead Sponsor
- Department of Transfusion Medicine PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
GBS patient chosen for the study purpose within four weeks of onset of weakness following Ausbury criteria and ranging from 13 to 60 years of age.
1. Duration of illness more than 30 days before entry in study.
2. Children less than or equal to 12 year of age.
3. Any contraindication for IVIG or TPE.
4. Patient with hypokalemia and porphyria.
5. Specific exclusions with atypical features such as--
a.Purely sensory symptoms.
b.Cranial nerve palsies without significant limb weakness.
c.Previous acute polyneuropathy.
d.Improvement of one or more disability grades before inclusion
e.Pregnancy.
f. Previous therapy with immunosuppressive drugs other than steroids.
g. Previous plasmapheresis / IVIG therapy.
h. Patient not willing to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incremental cost per unit recovery in grade of Guillain Barre syndrome disability scoreTimepoint: Time horizon for the study was 12 weeks during which all major effects and costs were assessed and outcome at 12 weeks were measured.
- Secondary Outcome Measures
Name Time Method comparing other tools( MRC SUM SCORE AND ONLS SCORE) for assessment for functional improvement in GBSTimepoint: Time horizon for the study was 12 weeks during which all major effects and costs were assessed and outcome at 12 weeks were measured.